Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice

References

• Colombo C, Littlewood J. The implementation of standards of care in Europe: state of the art. J Cyst Fibros 2011;10(Suppl 2):S7-15
   Google Scholar
• Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Med 2012;10:88
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation patient registry. Cystic Fibrosis Foundation; Bethesda, Maryland: 2012
   Google Scholar
• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245(4922):1066-73
   PubMed Web of Science ®Google Scholar
• Drumm ML, Collins FS. Molecular biology of cystic fibrosis. Mol Genet Med 1993;3:33-68
   Google Scholar
• Quinton PM. Cystic fibrosis: lessons from the sweat gland. Physiology (Bethesda) 2007;22:212-25
   PubMed Web of Science ®Google Scholar
• Barrett PM, Alagely A, Topol EJ. Cystic fibrosis in an era of genomically guided therapy. Hum Mol Genet 2012;21(R1):R66-71
   PubMed Web of Science ®Google Scholar
• Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996;154(5):1229-56
   Web of Science ®Google Scholar
• Geddes DM, Shiner R. Cystic fibrosis – from lung damage to symptoms. Acta Paediatr Scand Suppl 1989;363:52-6; discussion 56-57
   Google Scholar
• Nichols D, Chmiel J, Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clin Rev Allergy Immunol 2008;34(2):146-62
   PubMed Web of Science ®Google Scholar
• Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29(3):522-6
   PubMed Web of Science ®Google Scholar
• Tonelli AR, Fernandez-Bussy S, Lodhi S, et al. Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survival. J Heart Lung Transplant 2010;29(8):865-72
   Google Scholar
• Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166(12 Pt 1):1550-5
   PubMed Web of Science ®Google Scholar
• Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007;62(4):360-7
   PubMed Web of Science ®Google Scholar
• Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103(6):e72
   PubMed Web of Science ®Google Scholar
• Rosenberg MA, Farrell PM. Assessing the cost of cystic fibrosis diagnosis and treatment. J Pediatr 2005;147(3 Suppl):S101-5
   Google Scholar
• Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121(1):64-72
   PubMed Web of Science ®Google Scholar
• Amadori A, Antonelli A, Balteri I, et al. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med 2009;103(3):407-13
   Google Scholar
• de Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66(8):680-5
   PubMed Web of Science ®Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331(10):637-42
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation. Microbiology and infectious disease in cystic fibrosis. Volume V. Cystic Fibrosis Consensus Conference, May 17-18, 1994. p. 1-26
   Google Scholar
• Kanga J, Kuhn R, Craigmyle L, et al. Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation. Clin Ther 1999;21(8):1343-56
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139(3):359-65
   PubMed Web of Science ®Google Scholar
• Bilton D, Canny G, Conway S, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 2011;10(Suppl 2):S79-81
   PubMedGoogle Scholar
• Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001;31(6):436-42
   PubMed Web of Science ®Google Scholar
• Abbott J, Holt A, Hart A, et al. What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis. J Cyst Fibros 2009;8(5):356-9
   Google Scholar
• Anstead M, Saiman L, Mayer-Hamblett N, et al. Pulmonary exacerbations in CF patients with early lung disease. J Cyst Fibros 2014;13(1):74-9
   Google Scholar
• Byrnes CA, Vidmar S, Cheney JL, et al. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. Thorax 2013;68(7):643-51
   PubMed Web of Science ®Google Scholar
• Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011;46(9):870-81
   PubMed Web of Science ®Google Scholar
• Bradley JM, Blume SW, Balp MM, et al. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J 2013;41(3):571-7
   Google Scholar
• Jarad NA, Giles K. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis. Chron Respir Dis 2008;5(1):29-33
   Google Scholar
• Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004;37(5):400-6
   PubMed Web of Science ®Google Scholar
• Wagener JS, Rasouliyan L, VanDevanter DR, et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2013;48(7):666-73
   PubMed Web of Science ®Google Scholar
• Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141(4 Pt 1):914-21
   Google Scholar
• Smith AL, Doershuk C, Goldmann D, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999;134(4):413-21
   Google Scholar
• Fodor AA, Klem ER, Gilpin DF, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 2012;7(9):e45001
   PubMed Web of Science ®Google Scholar
• Reid DW, Latham R, Lamont IL, et al. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 2013;12(6):688-99
   Google Scholar
• Aaron SD, Ramotar K, Ferris W, et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2004;169(7):811-15
   PubMed Web of Science ®Google Scholar
• VanDevanter DR, Van Dalfsen JM. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? Pediatr Pulmonol 2005;39(6):504-6
   Google Scholar
• Wark PA, Tooze M, Cheese L, et al. Viral infections trigger exacerbations of cystic fibrosis in adults and children. Eur Respir J 2012;40(2):510-12
   Google Scholar
• Asner S, Waters V, Solomon M, et al. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 2012;11(5):433-9
   PubMed Web of Science ®Google Scholar
• Hoek RA, Paats MS, Pas SD, et al. Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients. Scand J Infect Dis 2013;45(1):65-9
   PubMed Web of Science ®Google Scholar
• Chattoraj SS, Ganesan S, Jones AM, et al. Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells. Thorax 2011;66(4):333-9
   PubMed Web of Science ®Google Scholar
• Kong M, Maeng P, Hong J, et al. Respiratory syncytial virus infection disrupts monolayer integrity and function in cystic fibrosis airway cells. Viruses 2013;5(9):2260-71
   Google Scholar
• Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci USA 2012;109(34):13769-74
   PubMed Web of Science ®Google Scholar
• Block JK, Vandemheen KL, Tullis E, et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax 2006;61(11):969-74
   Google Scholar
• Collaco JM, Blackman SM, McGready J, et al. Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J Pediatr 2010;157(5):802-7; e801-803
   PubMed Web of Science ®Google Scholar
• Smyth A, O’Hea U, Williams G, et al. Passive smoking and impaired lung function in cystic fibrosis. Arch Dis Child 1994;71(4):353-4
   PubMed Web of Science ®Google Scholar
• Beydon N, Amsallem F, Bellet M, et al. Pulmonary function tests in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2002;166(8):1099-104
   Google Scholar
• Campbell PW3rd, Parker RA, Roberts BT, et al. Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion. J Pediatr 1992;120(2 Pt 1):261-264
   Google Scholar
• Rubin BK. Exposure of children with cystic fibrosis to environmental tobacco smoke. N Engl J Med 1990;323(12):782-8
   PubMed Web of Science ®Google Scholar
• Collaco JM, Vanscoy L, Bremer L, et al. Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA 2008;299(4):417-24
   PubMed Web of Science ®Google Scholar
• O’Connor GT, Quinton HB, Kneeland T, et al. Median household income and mortality rate in cystic fibrosis. Pediatrics 2003;111(4 Pt 1):e333-9
   PubMed Web of Science ®Google Scholar
• Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001;163(6):1331-7
   PubMed Web of Science ®Google Scholar
• Schechter MS, Margolis PA. Relationship between socioeconomic status and disease severity in cystic fibrosis. J Pediatr 1998;132(2):260-4
   PubMed Web of Science ®Google Scholar
• Curtis JR, Burke W, Kassner AW, Aitken ML. Absence of health insurance is associated with decreased life expectancy in patients with cystic fibrosis. Am J Respir Crit Care Med 1997;155(6):1921-4
   PubMed Web of Science ®Google Scholar
• Goss CH, Newsom SA, Schildcrout JS, et al. Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am J Respir Crit Care Med 2004;169(7):816-21
   PubMed Web of Science ®Google Scholar
• Collaco JM, McGready J, Green DM, et al. Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS One 2011;6(11):e27784
   PubMed Web of Science ®Google Scholar
• Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011;10(4):258-64
   PubMed Web of Science ®Google Scholar
• Sequeiros IM, Jarad N. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis 2012;9(1):9-16
   Web of Science ®Google Scholar
• Vermeulen F, Proesmans M, Boon M, et al. Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. Thorax 2014;69(1):39-45
   PubMed Web of Science ®Google Scholar
• Gifford AH. Hemoglobin ≤12.9 g/dl predicts risk of antibiotic treatment in cystic fibrosis. J Cyst Fibros 2014;13(1):114-15
   Google Scholar
• Chotirmall SH, Smith SG, Gunaratnam C, et al. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 2012;366(21):1978-86
   PubMed Web of Science ®Google Scholar
• Robson M, Abbott J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992;47(9):684-9
   PubMed Web of Science ®Google Scholar
• Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med 2005;172(1):99-104
   PubMed Web of Science ®Google Scholar
• Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40(1):61-6
   PubMed Web of Science ®Google Scholar
• Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182(5):627-32
   PubMed Web of Science ®Google Scholar
• Sanders DB, Hoffman LR, Emerson J, et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010;45(2):127-34
   PubMed Web of Science ®Google Scholar
• Collaco JM, Green DM, Cutting GR, et al. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010;182(9):1137-43
   PubMed Web of Science ®Google Scholar
• Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153(4):345-52
   PubMed Web of Science ®Google Scholar
• FitzGerald JM. Targeting lung attacks. Thorax 2011;66(5):365-6
   Google Scholar
• Bush A, Pavord I. Following Nero: fiddle while Rome burns, or is there a better way? Thorax 2011;66(5):367
   Google Scholar
• Rogers GB, Hoffman LR, Johnson MW, et al. Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset. Expert Rev Mol Diagn 2011;11(2):197-206
   PubMed Web of Science ®Google Scholar
• Shoki AH, Mayer-Hamblett N, Wilcox PG, et al. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 2013;144(5):1659-70
   PubMed Web of Science ®Google Scholar
• Kraynack NC, McBride JT. Improving care at cystic fibrosis centers through quality improvement. Semin Respir Crit Care Med 2009;30(5):547-58
   Google Scholar
• Gifford AH, Alexandru DM, Li Z, et al. Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis. J Cyst Fibros 2014;13(3):311-18
   Google Scholar
• Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3 – Management. Thorax 2008;63(2):180-4
   PubMed Web of Science ®Google Scholar
• Flume PA, Mogayzel PJJr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180(9):802-8
   PubMed Web of Science ®Google Scholar
• Ryan G, Jahnke N, Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 2012;12:CD008319
   PubMedGoogle Scholar
• Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatr Pulmonol 2013;48(6):525-37
   PubMed Web of Science ®Google Scholar
• Bell SC, Robinson PJ. Exacerbations in cystic fibrosis: 2. prevention. Thorax 2007;62(8):723-32
   Google Scholar
• Mogayzel PJJr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-9
   PubMed Web of Science ®Google Scholar
• Máiz L, Giron RM, Olveira C, et al. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin Pharmacother 2013;14(9):1135-49
   PubMed Web of Science ®Google Scholar
• Sanchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. Allergol Immunopathol (Madr) 2013. [Epub ahead of print]
   Google Scholar
• Doring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11(6):461-79
   PubMed Web of Science ®Google Scholar
• Oermann CM, McCoy KS, Retsch-Bogart GZ, et al. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother 2011;66(10):2398-404
   Google Scholar
• Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013;12(2):130-40
   PubMed Web of Science ®Google Scholar
• GINA Report, Global Strategy For Asthma Management and Prevention. Updated December 2012 2012. Available from: http://ginasthma.org [Last accessed June 2014]
   Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014. Available from: http://goldcopd.org [Last accessed June 2014]
   Google Scholar
• Cantón R, Maiz L, Escribano A, et al. [Consenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quística]. Arch Bronconeumol 2015; pii: S0300-2896(14)00487-6. doi: 10.1016/j.arbres.2014.09.021. [Epub ahead of print]
   Google Scholar